The Bank of Nova Scotia

The Bank of Nova Scotia (NYSE: BNS) is a leading bank operating in the Americas. It offers a portfolio of banking advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets.

Key Highlights

• BNS reported only a 0.30% growth in total revenue to CAD 7.76 billion in Q3FY21 (ended July 31, 2021) compared to CAD 7.73 billion in Q3FY20.
• The company's assets, as of July 31, 2021, amounted to CAD 1.16 trillion.
• Net income for Q3FY21 was CAD 2.54 billion, increasing 94.94% from CAD 1.30 billion reported in Q3FY20, resulting from a reduction in the amount of provision for credit losses.
• On August 26, 2021, BNS stated that it made new updates to its mobile app, enhancing its customers' digital experience.
• On August 24, 2021, the company declared a dividend of CAD 0.90 per common share, payable on October 27, 2021, to shareholders of record on October 05, 2021.
• BNS' Efficiency Ratio for Q3FY21 was 52.1%, lower than the industry median of 56.4%.
• Stock is currently trading between its crucial short-term (50-day) as well as long-term (200-day) SMA support levels.
• Stock is currently at the higher end of the 52-week range of USD 40.16 to USD 68.02.

Technical Price Chart (as of August 26, 2021). Analysis by Kalkine

Conclusion: BNS' stock price increased 26.85% in the last nine months, and its RSI Index is 48.14. Considering the decent fundamentals, robust dividend yield, technical indicators, and current valuation, we recommend a "Watch" rating on the stock at the current price of USD 63.08, down 1.47% as of August 26, 2021, 1:52 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a commercial-stage biopharmaceutical company with a primary focus on the innovation and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for treating rare diseases.

Key Highlights

• SRPT reported a 19.46% growth in total revenue to USD 164.09 million in Q2FY21 (ended June 30, 2021) compared to USD 137.36 million in Q2FY20.
• Net loss for Q2FY21 was USD 81.41 million vs. a net loss of USD 150.82 million reported in Q2FY20, resulting from a USD 102.00 million gain recorded from the sale of the Priority Review Voucher completed in April 2021.
• The company exited the quarter with a cash balance (including short-term investments) of USD 1.73 billion and a total debt of USD 1.09 billion.
• On August 04, 2021, SRPT signed a license agreement for calpain 3 (CAPN-3), an investigational gene therapy candidate to treat Limb-girdle muscular dystrophy type 2A (LGMD2A). CAPN-3 is an Abigail Wexner Research Institute development.
• SRPT's EBITDA and operating margin for Q2FY21 were -97.0% and -102.1%, respectively.
• Stock is currently trading between its crucial short-term (50-day) as well as long-term (200-day) SMA support levels.
• Stock is currently at the lower end of the 52-week range of USD 65.30 to USD 181.83.

Technical Price Chart (as of August 26, 2021). Analysis by Kalkine

Conclusion: SRPT's stock price increased 19.50% in the last month, and its RSI Index is 57.69. Considering the meagre fundamentals, disappointing profit margins, other technical indicators, and current trading levels, we recommend an "Avoid" rating on the stock at the current price of USD 79.16, down 0.98% as of August 26, 2021, 1:56 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.  

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.